RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma | MicrobiomeTrials← Back to trialsNCT07150806
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-11-12Est. Completion: 2026-12-31
Enrollment target: 30 participants Locations- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Other microbiome trials you might be interested in
Solid Tumor CancerMedulloblastomaHigh Risk NeuroblastomaHigh Grade GliomasMeningiomaParagangliomaPheochromocytomaNeuroendocrine Tumours (NET)Adrenal TumoursDIPGGlioblastomaGlioblastoma (GBM)Osteosarcoma RecurrentCarcinoma AdrenalSynovial SarcomasEsthesioneuroblastomaNeuroblastoma RecurrentSolid Tumor Refractory to Conventional Treatment
Medulloblastoma Recurrent
Paraganglioma/ Phaeochromocytoma
Ependymoma
Ependymoma Recurrent
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment…
Boadilla del Monte, SpainEst. completion Jul 2029
Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work…
Birmingham, United StatesEst. completion Jan 1, 2027
High Grade Meningioma
This is a randomized, controlled, open-label, multicenter, Phase III clinical study designed to compare the efficacy and…
Multiple LocationsEst. completion Jul 31, 2029